We anticipate acceptable acute toxicities and favorable short-term control of PSA in intermediate- and high-risk prostate cancer patients who receive the combination treatment of ADT, WPRT, and SBRT boost. The gene discussed is KLK3; the disease is Familial prostate cancer.